A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis
Author:
Publisher
Elsevier BV
Subject
Immunology,Immunology and Allergy
Reference55 articles.
1. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring;Kappos;Lancet Neurol,2007
2. The role of stress in the mosaic of autoimmunity: an overlooked association;Sharif;Autoimmun Rev,2018
3. Polymerase-1 pathway activation in acute multiple sclerosis relapse;Achiron;Autoimmun Rev,2018
4. Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: a systematic review;Merkel;Autoimmun Rev,2017
5. Natalizumab in multiple sclerosis: long-term management;Clerico;Int J Mol Sci,2017
Cited by 46 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cell-Mediated Immunity in Multiple Sclerosis Patients Who Discontinued Therapy with an Integrin Inhibitor;Annals of Clinical and Experimental Neurology;2024-04-05
2. Ocrelizumab use in multiple sclerosis: a real-world experience in a changing therapeutic scenario;Neurological Sciences;2024-03-12
3. Mapping the Therapeutic Options for Multiple Sclerosis in Brazil: A Comprehensive Analysis;Sclerosis;2024-02-06
4. The Epigenetic Roles of Bet Inhibitors Jq1 and I-Bet726 in Regulating Inflammation and Treatment for Experimental Autoimmune Encephalomyelitis;2024
5. Long-term outcome of natalizumab-associated progressive multifocal leukoencephalopathy in Austria: a nationwide retrospective study;Journal of Neurology;2023-09-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3